{"id":430,"date":"2022-05-03T09:00:43","date_gmt":"2022-05-03T09:00:43","guid":{"rendered":"http:\/\/wpdemo.archiwp.com\/maxbizz\/?p=430"},"modified":"2022-05-22T21:40:24","modified_gmt":"2022-05-22T21:40:24","slug":"the-future-of-retail-asias-ecosystems","status":"publish","type":"post","link":"https:\/\/bethelsystems.com\/?p=430","title":{"rendered":"Intellectual Property"},"content":{"rendered":"<div class=\"feedzy-rss feedzy-0e65c6665ca776f6e4205d072c954d33\"><ul><li  style=\"padding: 15px 0 25px\" class=\"rss_item\"><span class=\"title\"><a href=\"https:\/\/ipwatchdog.com\/2026\/11\/04\/second-circuit-follows-third-circuit-in-applying-broad-use-definition-for-dtsa-misappropriation-claims\/\" target=\"_blank\" rel=\" noopener\">Second Circuit Follows Third Circuit in Applying Broad \u2018Use\u2019 Definition for DTSA Misappropriation Claims<\/a><\/span><div class=\"rss_content\" style=\"\"><small>by <a href=\"\/\/ipwatchdog.com\" target=\"_blank\" title=\"ipwatchdog.com\" >Steve Brachmann<\/a> on November 4, 2026 at 10:15 pm <\/small><p>Yesterday, the U.S. Court of Appeals for the Second Circuit reversed and remanded the Southern District of New York\u2019s dismissal of trade secret misappropriation claims filed against fintech company Arcesium by rival SS&amp;C Technologies. Deciding that a broad definition of \u201cuse\u201d under the Defend Trade Secrets Act (DTSA) was consistent with Second Circuit case law, the appellate court held that the district court erred in finding no misappropriation of SS&amp;C\u2019s alleged trade secrets and improperly credited Arcesium\u2019s explanation of emails attached to SS&amp;C\u2019s complaint at the motion to dismiss stage.\nThe post Second Circuit Follows Third Circuit in Applying Broad \u2018Use\u2019 Definition for DTSA Misappropriation Claims appeared first on IPWatchdog.com | Patents &amp; Intellectual Property Law.<\/p><\/div><\/li><li  style=\"padding: 15px 0 25px\" class=\"rss_item\"><span class=\"title\"><a href=\"https:\/\/ipwatchdog.com\/2026\/11\/04\/cjeu-advocate-general-outlines-copyright-limits-for-ai-news-summaries\/\" target=\"_blank\" rel=\" noopener\">CJEU Advocate General Outlines Copyright Limits for AI News Summaries<\/a><\/span><div class=\"rss_content\" style=\"\"><small>by <a href=\"\/\/ipwatchdog.com\" target=\"_blank\" title=\"ipwatchdog.com\" >Eileen McDermott<\/a> on November 4, 2026 at 7:15 pm <\/small><p>Advocate General Maciej Szpunar of the Court of Justice of the European Union (CJEU) issued an opinion on Tuesday in the first case on generative AI to reach the Court. The opinion ultimately held that \u201cthe retrieval and reuse, in real time, of online press publications by AI chatbots in order to generate answers to user queries may, in certain circumstances, infringe the rights of press publishers.\u201d The opinion is nonbinding on the CJEU.\nThe post CJEU Advocate General Outlines Copyright Limits for AI News Summaries appeared first on IPWatchdog.com | Patents &amp; Intellectual Property Law.<\/p><\/div><\/li><li  style=\"padding: 15px 0 25px\" class=\"rss_item\"><span class=\"title\"><a href=\"https:\/\/ipwatchdog.com\/2026\/11\/04\/rare-disease-treatment-patents-after-amgen-can-claims-cover-untested-genetic-mutations\/\" target=\"_blank\" rel=\" noopener\">Rare Disease Treatment Patents after Amgen: Can Claims Cover Untested Genetic Mutations?<\/a><\/span><div class=\"rss_content\" style=\"\"><small>by <a href=\"\/\/ipwatchdog.com\" target=\"_blank\" title=\"ipwatchdog.com\" >Konstantin Voropaev<\/a> on November 4, 2026 at 2:15 pm <\/small><p>On October 14, 2026, the Food and Drug Administration (FDA) announced the Rare Disease Framework Initiative. The goal of this effort is quite essential for patients with rare (orphan) diseases \u2013 to develop an approach for assessing medicines for orphan diseases with a focus on the evidence that can be gathered for this assessment. The FDA proposes to include disease characteristics, patient needs, patient population size, and characteristics of orphan medications. The initiative does not itself establish new approval standards. Although the initiative relates to regulatory evidence matters, it also raises a separate legal question about the evidence needed to support patent claim scope.\nThe post Rare Disease Treatment Patents after &lt;i&gt;Amgen&lt;\/i&gt;: Can Claims Cover Untested Genetic Mutations? appeared first on IPWatchdog.com | Patents &amp; Intellectual Property Law.<\/p><\/div><\/li><li  style=\"padding: 15px 0 25px\" class=\"rss_item\"><span class=\"title\"><a href=\"https:\/\/ipwatchdog.com\/2026\/11\/03\/when-ai-adoption-outpaces-ip-protection-risks\/\" target=\"_blank\" rel=\" noopener\">When AI Adoption Outpaces IP Protection: The Risks Companies Must Address | IPWatchdog Unleashed<\/a><\/span><div class=\"rss_content\" style=\"\"><small>by <a href=\"\/\/ipwatchdog.com\" target=\"_blank\" title=\"ipwatchdog.com\" >Gene Quinn<\/a> on November 3, 2026 at 9:15 pm <\/small><p>This week on IPWatchdog Unleashed, we have a discussion about the IP risks associated with AI use and adoption, with Stephanie Curcio, Marlene Valderrama, Kendra Ervin and Rinat Shangeeta. The discussion reveals a consequential gap with how businesses are deploying AI. Many companies are moving faster to adopt AI than their governance, contracting and IP review processes can accommodate. For those responsible for protecting innovation and confidential information, the challenge is ensuring that enthusiasm for AI adoption does not obscure the consequences of how these tools are actually used.\nThe post When AI Adoption Outpaces IP Protection: The Risks Companies Must Address | &lt;i&gt;IPWatchdog Unleashed&lt;\/i&gt; appeared first on IPWatchdog.com | Patents &amp; Intellectual Property Law.<\/p><\/div><\/li><\/ul> <\/div>","protected":false},"excerpt":{"rendered":"<p>Most firms have set up a war room to triage their immediate response to the crisis. But the lack of visibility around future demand complicates efforts to restart stalled portfolio companies&#8230;<\/p>\n","protected":false},"author":1,"featured_media":1666,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-430","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-intellectual-property"],"_links":{"self":[{"href":"https:\/\/bethelsystems.com\/index.php?rest_route=\/wp\/v2\/posts\/430","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bethelsystems.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bethelsystems.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bethelsystems.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bethelsystems.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=430"}],"version-history":[{"count":5,"href":"https:\/\/bethelsystems.com\/index.php?rest_route=\/wp\/v2\/posts\/430\/revisions"}],"predecessor-version":[{"id":2306,"href":"https:\/\/bethelsystems.com\/index.php?rest_route=\/wp\/v2\/posts\/430\/revisions\/2306"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bethelsystems.com\/index.php?rest_route=\/wp\/v2\/media\/1666"}],"wp:attachment":[{"href":"https:\/\/bethelsystems.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=430"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bethelsystems.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=430"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bethelsystems.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=430"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}